CompletedNCT01233115Updated Aug 30, 2011

LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy

An observational study in Age-Related Macular Degeneration, sponsored by Kyungpook National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-08-30.

Sponsored by Kyungpook National University Hospital · Observational

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 70
Ages: 60 Years to 80 Years
Sex: All

Study summary

This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients with polypoidal choroidal vasculopathy.

Read the detailed description

This is a retrospective cohort study comprised of 70 eyes being treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections. Patients were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638).

Conditions studied

Age-Related Macular Degeneration

Browse trials for

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's enrollment of 70 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Kyungpook National University Hospital is the lead sponsor of 76 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 60 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

The authors did a retrospective chart review of 70 patients with PCV who were treated at the Department of Ophthalmology, Kyungpook National University Hospital in Daegu, Korea.

Inclusion criteria

patients older than 60 years of age at onset
polyp-like terminal aneurysmal dilations with or without branching vascular networks in indocyanine green angiography (ICGA) and subretinal reddish-orange protrusions corresponding to polyp-like lesions
patients who had combined photodynamic therapy and intravitreal bevacizumab injections, and followed up for more than 12 months after the first treatment

Exclusion criteria

Exclusion Criteria:

patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV
patients who refused genotypic analyses

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 70 participants (actual)
Biospecimen retention: Samples with dna

Groups and cohorts

polypoidal choroidal vasculopathy
patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections

What researchers measure

Primary outcomes

Best-corrected visual acuity
Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA up to 12 months
Time frame: up to 12 months

Secondary outcomes

Angiographic characteristics
Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany) was evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.
Time frame: up to 12 months

Study locations

1 site

In Taek Kim
Daegu, Kyungsangpookdo 700-721, Korea, Republic of

References and documents

Publications

Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2010 Nov-Dec;30(10):1616-21. doi: 10.1097/IAE.0b013e3181e587e3. PubMed 20671585 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Aug 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01233115
Lead sponsor: Kyungpook National University Hospital
Responsible party: Dong Ho Park (clinical professor, Kyungpook National University Hospital) — Principal investigator
First posted: Nov 3, 2010
Start date: Oct 2010
Primary completion: Aug 2011
Completion: Aug 2011
Last update: Aug 30, 2011

Study contacts

In Taek Kim, M.D.

principal investigator · Kyungpook National University Hospital

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration→

Other studies from this sponsor

Kyungpook National University Hospital

Start the discussion